Contraception最新文献

{"title":"Potassium chloride intracardiac fetal injection and tissue degeneration at fetal autopsy following induction abortion.","authors":"Kelvin Chui, Jefferson Terry, Jennifer A Hutcheon, Chantal Mayer, Jessica Liauw","doi":"10.1016/j.contraception.2025.110986","DOIUrl":"https://doi.org/10.1016/j.contraception.2025.110986","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the impact of potassium chloride intracardiac injection (KCl) on tissue degeneration at fetal autopsy, which may help inform termination care and autopsy expectations.</p><p><strong>Study design: </strong>In this retrospective cohort of induction abortions with fetal autopsies (N=266), we estimated the association between KCl and fetal tissue degeneration (qualitative assessment and quantitative ratio of basophilia:eosinophilia). We used log binomal and linear regression to calculate risk ratios and mean differences with 95% confidence intervals.</p><p><strong>Results: </strong>Those who received KCl were more likely to have qualitative tissue degeneration than those who did not (RR 2.8 [95% CI 1.3-6.1]). Quantitative basophilia:eosinophilia ratios were lower among those with KCl (mean difference in cardiac tissues of -0.031 [95%CI -0.039 to -0.023]), which further supports increased tissue degeneration in these cases.</p><p><strong>Conclusions: </strong>Fetal autopsies from induction abortions that had KCl fetal injection had increased risk of tissue degeneration compared with those that did not.</p>","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110986"},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three cases of second trimester uterine evacuation in patients with partially or undiagnosed Mullerian anomalies.","authors":"Kaleigh Olmsted, Amber Priester, Annika Van Oosbree, Madalyn Snoddy, Angela Dempsey","doi":"10.1016/j.contraception.2025.110985","DOIUrl":"https://doi.org/10.1016/j.contraception.2025.110985","url":null,"abstract":"<p><p>Mullerian anomalies complicate abortion care. Published experience to guide clinicians is scant. We present three cases of second trimester procedural abortion in patients with undiagnosed or partially diagnosed Mullerian anomalies and offer strategies that clinicians may implement when caring for similar patients.</p>","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110985"},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safeguarding Autonomy: Examining the Complexities and Implications of Under-Regulated Period-Tracking Apps and Paired Devices in a Post-Roe Landscape.","authors":"Bridget G Kelly, Ornsiree Junchaya, Jie Min, Michael Burdan","doi":"10.1016/j.contraception.2025.110981","DOIUrl":"https://doi.org/10.1016/j.contraception.2025.110981","url":null,"abstract":"<p><p>Period-tracking applications (PTA) and paired data-tracking devices have become popular tools for promoting reproductive health, offering features to monitor menstrual cycles and track fertility. However, these apps present significant concerns regarding the privacy of sensitive health data as the current legal landscape provides inadequate coverage to ensure user safety, leaving the collection, usage, management, and disclosure of data to be determined by company leaders. While the Federal Trade Commission (FTC) has regulatory mechanisms to hold PTAs accountable for their business practices, security concerns remain. Fears around personal health data security have intensified after the U.S. Supreme Court's 2022 decision to overturn Roe v. Wade as experts warn digital reproductive health data derived from PTAs could be used as criminal evidence in states with abortion restrictions. In the absence of a federal standard protecting the right to abortion, a comprehensive approach to safeguarding digital reproductive health data is required to ensure PTAs can remain health literacy tools that promote reproductive health and autonomy. This commentary reviews the current regulatory environment in the U.S. regarding PTAs, highlighting the risks to user privacy and data security-as evidenced by the 2020 FTC complaint against Flo Health, Inc. for sharing sensitive user data with third parties-and the broader implications of regulatory gaps in a post-Roe landscape.</p>","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110981"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interest in period pills in the United States: a nationally representative survey, 2021-2022.","authors":"Ushma D Upadhyay, Cari Sietstra, Leah Koenig, Jennifer Ko, M Antonia Biggs","doi":"10.1016/j.contraception.2025.110980","DOIUrl":"https://doi.org/10.1016/j.contraception.2025.110980","url":null,"abstract":"<p><strong>Objectives: </strong>Period pills are a method used to induce bleeding when a menstrual period is late and pregnancy is suspected but not confirmed. This practice enables people to ensure they are not pregnant, without first confirming the existence of a pregnancy. We aimed to measure the extent of interest in period pills.</p><p><strong>Methods: </strong>We used data from a nationally representative panel survey implemented December 2021-January 2022 among people ages 15-49 assigned female sex at birth to explore interest in and support for period pills after reading descriptive information about them. We estimated the weighted national prevalence of interest in potentially using the pills and support for their availability. We used weighted bivariate logistic regression to examine factors associated with these two outcomes.</p><p><strong>Results: </strong>Among the 6,964 participants in the analytic sample, one-quarter (24%, 95% CI: 22%, 25%) reported that they would consider personally using period pills, and another 19% (95% CI: 17%, 20%) were uncertain. Half of participants (52%, 95% CI: 50%, 53%) said they were in favor of period pills being available, and another 24% (95% CI: 23%, 26%) were uncertain. Factors associated with both considering using or supporting their availability include being ages 18-29 (vs. 40-49), completing college, never having been married, having a prior abortion, identifying as LGBQ+, and having experienced barriers to sexual and reproductive health services.</p><p><strong>Conclusions: </strong>There is substantial public interest in and support for period pills, which supports expanding options that enable people to control their fertility.</p><p><strong>Implications: </strong>Given the substantial interest in period pills found in this study, clinicians should consider offering them as an additional option to control their fertility.</p>","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110980"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"The effects of Implanon on lipid metabolism in comparison with Norplant\" [Contraception 60 (1999) 281-287].","authors":"Suharti K Suherman, Biran Affandi, Tjeerd Korver","doi":"10.1016/j.contraception.2025.110947","DOIUrl":"10.1016/j.contraception.2025.110947","url":null,"abstract":"","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110947"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist prescribed contraception using clinical protocols: A review of the grey literature.","authors":"Victoria Chisari, Helen Benson, Shalom Charlie Benrimoj, Therese Foran, Sarah Dineen-Griffin, Kylie Williams","doi":"10.1016/j.contraception.2025.110979","DOIUrl":"https://doi.org/10.1016/j.contraception.2025.110979","url":null,"abstract":"<p><strong>Background: </strong>Many women face barriers to starting and continuing contraception due to difficulties in accessing primary care. Pharmacist-prescribed contraceptives has emerged as a strategy to improve access. This approach offers an additional pathway for women to access contraceptive care, with benefits such as lower costs, shorter wait times, and extended hours.</p><p><strong>Objective: </strong>This review aims to analyze clinical protocols used by community pharmacists to prescribe and continue hormonal contraceptives and evaluate their quality.</p><p><strong>Methods: </strong>This review utilized grey literature since protocols are often not formally published. The search involved four processes: searching a grey literature database, using Google, reviewing health agency websites, and consulting international experts. Records were included if they met the definition of a clinical protocol, were for community pharmacist prescribing or continuation of hormonal contraception and were written in English. Grounded Theory was used for analysis. Quality appraisal was performed using the AGREE II tool.</p><p><strong>Results: </strong>Thirty clinical protocols were identified from the USA (n = 23), Canada (n = 2), the UK (n = 2), New Zealand (n = 1), and Australia (n = 2). Pharmacists were authorized to prescribe and continue contraceptives in 27 protocols and continue contraceptives only in three. Key requirements included age restrictions, measurement of blood pressure and body mass index, review by a health professional, patient self-completed screening tools and use of best-practice guidelines. The lowest scoring domains in the quality assessment were 'Editorial Independence', 'Applicability' and 'Rigor of Development'.</p><p><strong>Conclusion: </strong>The review provides insights into the current international landscape of pharmacist-prescribed contraception and highlights key components of clinical protocols. It offers valuable information for policymakers to support the development of frameworks for pharmacist-prescribed contraception globally.</p>","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110979"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144201057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"An integrated analysis of nonmenstrual adverse events with Implanon\" [Contraception 58 (1998) S109-S115].","authors":"J Urbancsek","doi":"10.1016/j.contraception.2025.110948","DOIUrl":"10.1016/j.contraception.2025.110948","url":null,"abstract":"","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110948"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon\" [Contraception 58 (1998) S99-S107].","authors":"B Affandi","doi":"10.1016/j.contraception.2025.110949","DOIUrl":"10.1016/j.contraception.2025.110949","url":null,"abstract":"","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110949"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Pharmacokinetics of Implanon: An integrated analysis\" [Contraception 58 (1998) S85-S90].","authors":"J Huber","doi":"10.1016/j.contraception.2025.110953","DOIUrl":"10.1016/j.contraception.2025.110953","url":null,"abstract":"","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110953"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to \"Insertion and removal of Implanon\" [Contraception 58 (1998) S79-S83].","authors":"L Mascarenhas","doi":"10.1016/j.contraception.2025.110951","DOIUrl":"10.1016/j.contraception.2025.110951","url":null,"abstract":"","PeriodicalId":93955,"journal":{"name":"Contraception","volume":" ","pages":"110951"},"PeriodicalIF":0.0,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}